Published in Antimicrob Agents Chemother on June 30, 2014
Modelling hepatitis C therapy--predicting effects of treatment. Nat Rev Gastroenterol Hepatol (2015) 0.84
A Model-Based Illustrative Exploratory Approach to Optimize the Dosing of Peg-IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple Therapy. CPT Pharmacometrics Syst Pharmacol (2014) 0.76
HCV Kinetic Models and Their Implications in Drug Development. CPT Pharmacometrics Syst Pharmacol (2015) 0.75
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Global epidemiology of hepatitis C virus infection. Lancet Infect Dis (2005) 16.44
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med (2009) 12.07
Telaprevir for retreatment of HCV infection. N Engl J Med (2011) 10.48
Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science (1998) 10.43
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol (2013) 5.64
Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology (2009) 3.89
Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology (2014) 3.52
Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med (2010) 2.82
Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature (2004) 2.74
Hepatitis C virus resistance to protease inhibitors. J Hepatol (2011) 2.18
The relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1. Clin Infect Dis (2012) 2.16
Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology (2004) 1.92
Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. Hepatology (2011) 1.87
Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders. Hepatology (2006) 1.69
A perspective on modelling hepatitis C virus infection. J Viral Hepat (2010) 1.67
Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut (2013) 1.63
A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants. PLoS Comput Biol (2010) 1.42
New virologic tools for management of chronic hepatitis B and C. Gastroenterology (2012) 1.41
Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. Lancet Infect Dis (2012) 1.40
Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection? J Viral Hepat (2012) 1.17
Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clin Gastroenterol Hepatol (2012) 1.16
High-performance liquid chromatographic determination of ribavirin in whole blood to assess disposition in erythrocytes. Antimicrob Agents Chemother (1999) 1.10
Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C. J Antimicrob Chemother (2008) 1.09
Estimation of dynamical model parameters taking into account undetectable marker values. BMC Med Res Methodol (2006) 1.08
Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents? Antivir Ther (2012) 1.07
Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir. Liver Int (2014) 1.06
Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). Hepatology (2012) 1.04
Efficacy and safety of telaprevir in patients with genotype 1 hepatitis C infection. Therap Adv Gastroenterol (2012) 1.03
A hepatitis C viral kinetic model that allows for time-varying drug effectiveness. Antivir Ther (2008) 1.00
Erythrocyte ribavirin concentration for assessing hemoglobin reduction in interferon and ribavirin combination therapy. Hepatol Res (2005) 0.99
A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection. PLoS Comput Biol (2012) 0.98
Guidelines for the diagnosis of uncomplicated cirrhosis. Gastroenterol Clin Biol (2007) 0.97
Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938. Antivir Ther (2014) 0.94
Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141). J Hepatol (2014) 0.93
Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection. J Viral Hepat (2011) 0.91
Clinical trial simulation to evaluate power to compare the antiviral effectiveness of two hepatitis C protease inhibitors using nonlinear mixed effect models: a viral kinetic approach. BMC Med Res Methodol (2013) 0.87
Impact of ribavirin priming on viral kinetics and treatment response in chronic hepatitis C genotype 1 infection. J Viral Hepat (2013) 0.82
Convenient biological assay for polyethylene glycol-interferons in patients with hepatitis C. Antimicrob Agents Chemother (2004) 0.81
Ribavirin plasma concentration predicts sustained virological response to peginterferon Alfa 2a plus ribavirin in previously treated HCV-HIV-coinfected patients. J Acquir Immune Defic Syndr (2009) 0.80
Highly sensitive determination of HCV protease inhibitors boceprevir (SCH 503034) and telaprevir (VX 950) in human plasma by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 0.77
Erythrocyte and plasma ribavirin concentrations in the assessment of early and sustained virological responses to pegylated interferon-alpha 2a and ribavirin in patients coinfected with hepatitis C virus and HIV. J Antimicrob Chemother (2012) 0.76